Amgen (NASDAQ: AMGN) has announced that Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents…
Eli Lilly and Company (NYSE: LLY) announced today positive top-line results from the SURMOUNT-1 three-year study, which evaluated the long-term efficacy and safety of tirzepatide (Zepbound® and Mounjaro®) for weight management and delaying the progression to diabetes in adults with…
Audax Private Equity (“Audax”) announced today that it has entered into a definitive agreement to acquire the Clinical Services business of Avantor, Inc. (NYSE: AVTR) (“Clinical Services” or “the Company”). The transaction is anticipated to close in the fourth quarter,…
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has announced its financial results for the second quarter of 2024. “This quarter marks a groundbreaking milestone in Duchenne muscular dystrophy (DMD) treatment, comparable to the discovery of dystrophin…
Vertex Announces Reimbursement Agreement with NHS England for CASGEVY™ Vertex has announced a new reimbursement agreement with NHS England, effective immediately, allowing eligible patients with transfusion-dependent beta thalassemia (TDT) to access CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy. This agreement…
Recent findings from the two-part, double-randomized GMMG-HD7 phase 3 study reveal that Sarclisa (isatuximab), combined with lenalidomide, bortezomib, and dexamethasone (RVd), significantly enhances progression-free survival (PFS) in newly diagnosed, transplant-eligible multiple myeloma (NDMM) patients. This combination therapy resulted in a…
Professional Pickleball Association (PPA Tour) player James Ignatowich has teamed up with IBSA USA to promote Licart® (diclofenac epolamine) topical system 1.3%. Licart is the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) patch approved by the U.S. Food and Drug Administration…
Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for mild to moderate Alzheimer’s Disease at the 17th Clinical Trials…
Today, a groundbreaking environmental health impact initiative was announced to assist those most vulnerable to extreme weather events, which can exacerbate existing chronic conditions. Initially, the initiative will focus on extreme heat events by providing timely excessive heat alerts and…
AbbVie today announced the completion of its acquisition of Cerevel Therapeutics (NASDAQ: CERE), making Cerevel a part of AbbVie. “AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions us for sustainable long-term performance into the next decade and…
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899) involving patients with unresectable stage III or IV melanoma whose…
The interim analysis of the AMPLIFY Phase III trial revealed promising results for AstraZeneca’s Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, in treating chronic lymphocytic leukaemia (CLL). The study showed a significant improvement in progression-free survival (PFS) compared…